Full Text of PDF (597k)
Article in Japanese
Abstract
Case Report
Response to nivolumab in a patient with squamous cell lung cancer and poor performance status
Daisuke Jingu Takehiro Yajima Satoshi Ubukata Makoto Shoji Hiroshi Takahashi Hiroshi Watanabe
Department of Respiratory Medicine, Saka General Hospital
ABSTRACT
A 74-year-old man with mutation-negative squamous cell lung carcinoma and carcinomatous pleuritis received chemotherapy at our hospital. At the end of the sixth-line therapy, his performance status (PS) was 3. After two cycles of nivolumab as seventh-line therapy, his PS improved to 1 and the tumor size was significantly reduced. Some patients with poor PS are sensitive to nivolumab, but the factors conferring sensitivity in these patients have still to be determined. Therefore, it is important to accumulate and study additional clinical data.
KEYWORDS
Nivolumab Non-small cell lung cancer Poor performance status Immune-checkpoint-inhibitor Immunotherapy
Received 4 Oct 2016 ／ Accepted 19 Jun 2017
AJRS, 6(5): 322-326, 2017
Copyright © The Japanese Respiratory Society All Rights Reserved.